Spyre Therapeutics (SYRE) was higher in the latest session as buying interest persisted after the company’s SPY001 Phase 2 SKYLINE Part A induction topline readout in moderate-to-severe ulcerative colitis (released April 13, 2026) triggered a sharp rerating in expectations for the program. The stock’s continued strength is also being supported by analyst commentary framing the data as supportive of a differentiated, potentially best-in-class monotherapy profile, keeping incremental demand elevated even after the initial post-data surge. (tipranks.com)

Another near-term driver is the company’s recently completed financing: Spyre closed an upsized underwritten public offering on April 16, 2026, selling 7,475,000 shares at $62.00 per share (including full exercise of the underwriters’ option) for gross proceeds of about $463.5 million. The close reduces near-term funding risk and can extend runway for multiple programs, but it also increases share count—creating a push-pull dynamic between de-risked funding and dilution that can still produce volatility. (biospace.com)

SYRE has also been benefiting from a rapid reset higher in price targets after the April 13 catalyst. Recent examples include a Jefferies price-target increase to $85 (from $47) and a Wells Fargo hike to $90 (from $50), reinforcing the market narrative that SPY001’s dataset may be strong enough to support a more valuable development path than previously modeled. (gurufocus.com)

With the stock trading well above the $62 offering price and near recent highs, the next leg likely depends on (1) more detailed clinical data disclosures and (2) updates on timing for additional proof-of-concept readouts in 2026 across Spyre’s pipeline. Any new efficacy/safety detail that confirms durability and differentiation for long-acting antibody dosing could further lift targets, while any signal of weaker-than-hoped separation versus incumbent therapies could reintroduce pressure given the sharper valuation and the larger post-offering float. (ir.spyre.com)